ProShare Advisors
NGNE icon

ProShare Advisors’s Neurogene NGNE Stock Holding History

ProShare Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-550
Closed -$20K – 2005
2022
Q1 		$20K Sell
550
-133
-19% -$7.76K ﹤0.01% 2174
2021
Q4 		$67K Buy
683
+4
+0.6% +$487 ﹤0.01% 2250
2021
Q3 		$98K Sell
679
-158
-19% -$24.2K ﹤0.01% 1919
2021
Q2 		$155K Buy
837
+116
+16% +$25.7K ﹤0.01% 2209
2021
Q1 		$177K Buy
721
+41
+6% +$10.5K ﹤0.01% 2071
2020
Q4 		$192K Buy
+680
New +$166K ﹤0.01% 1857
2017
Q4 		– Sell
-661
Closed -$188K – 1804
2017
Q3 		$188K Buy
661
+60
+10% +$17.2K ﹤0.01% 1291
2017
Q2 		$169K Sell
601
-24
-4% -$6.87K ﹤0.01% 1365
2017
Q1 		$209K Sell
625
-149
-19% -$52.3K ﹤0.01% 1432
2016
Q4 		$255K Buy
774
+231
+43% +$62.1K ﹤0.01% 1469
2016
Q3 		$145K Sell
543
-98
-15% -$19.8K ﹤0.01% 1386
2016
Q2 		$85K Buy
641
+9
+1% +$1.43K ﹤0.01% 1529
2016
Q1 		$112K Sell
632
-60
-9% -$11.7K ﹤0.01% 1506
2015
Q4 		$173K Buy
+692
New +$182K ﹤0.01% 1572

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProShare Advisors's NGNE Position: Q2 2022 in Review

ProShare Advisors sold out of Neurogene (NGNE) in Q2 2022, closing a stake of 550 shares — an estimated $20K sold.

ProShare Advisors first reported a position in NGNE in Q4 2015 and held it in 14 quarters. The position peaked at $255K in Q4 2016. 63 funds tracked by Wall St. Rank hold NGNE as of Q2 2022.

  • ProShare Advisors reported no remaining Neurogene position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 550 Neurogene shares in Q2 2022, an estimated $20K.
  • ProShare Advisors first reported a position in Neurogene in Q4 2015 and held it in 14 quarters.
  • ProShare Advisors's Neurogene position peaked at $255K in Q4 2016.
  • 63 funds tracked by Wall St. Rank held Neurogene as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.